Findings on Bladder-Brain Link May Point to Better Treatments for Problems in Sleep, Attention
PHILADELPHIA, July 29 /PRNewswire-USNewswire/ -- Bladder problems may
leave a mark on the brain, by changing patterns of brain activity, possibly
contributing to disrupted sleep and problems with attention. For one in six
Americans who have overactive bladder, the involuntary bladder contracti...
Studies Point to Benefits of Personalized Chemotherapy Dose Management in Colorectal Cancer
BETHLEHEM, Pa., May 2 /PRNewswire/ -- Can a blood test improve
treatment outcomes for colorectal cancer patients? Recently published
studies indicate that personalized chemotherapy dose management --
measuring drug levels in patients' blood and adjusting them for optimal
dosing -- can substant...
Two Point of Care Tests From Quest Diagnostics Receive FDA 510(k) Clearance
First step for performing important diagnostics in physician offices
MADISON, N.J., Nov. 1 /PRNewswire-FirstCall/ -- Quest Diagnostics
Incorporated (NYSE: DGX ), the nation's leading provider of diagnostic
testing, information and services, today announced that its HemoCue and
Cepheid Announces Termination of Contract With the Centers for Disease Control and Prevention to Develop Rapid Point of Care Test for Avian Influenza
SUNNYVALE, Calif., Sept. 21 /PRNewswire-FirstCall/ -- Cepheid (Nasdaq:
CPHD) today announced the termination of its contract with the Centers for
Disease Control and Prevention (CDC) for development of a rapid
point-of-care diagnostic to detect influenza viruses A and B, and the H5N1
Surgeon General's 'Call to Action' to Prevent DVT/PE Praised by NATT as Turning Point
TARRYTOWN, N.Y., Sept. 15 /PRNewswire-USNewswire/ -- The National
Alliance for Thrombosis and Thrombophilia (NATT) praised Acting Surgeon
General Rear Admiral Steven K. Galson, MD, MPH for issuing an historic
"Call to Action" (CTA) to prevent deep vein thrombosis (DVT) and pulmonary
Hemoglobin Testing at the Point of Care
Since the level of blood oxygenation can be an essential element of patient assessment, measurement of hemoglobin levels in the clinical setting is often desirable. In keeping with the recent trend to incorporate sophisticated technology into easily used point-of-care devices, recent products from...
CTMM Becomes One of the World's Largest Public-Private Partnerships in Translational Medical Research
...o funding for translational (bench-to-bedside)
medical research, making CTMM one of the largest public-private partnerships
in the world. This pivotal point
in the organisation's development firmly
positions the Netherlands as one of the world's leading destinations for
translational biomedical research.
Project Zero Delay Accelerates Drug's Path to Clinical Trial
...llaboration that we've cultivated through our strategic alliance," Bast said. The alliance agreement also includes a commitment to regular meetings, a point
of contact to remove obstacles, support of collaborative projects and a commitment to accelerate drug development.
"The next challenge," said B...
Estrogen Getting Cool Reception From Dermatologists for Mixed Results in Improving Appearance of Skin
... HRT could be at an increased risk for breast cancer and that the overall health risks of this therapy could outweigh the possible benefits. From that point
on, HRT was prescribed more conservatively with lower dosing options and individualization based on each woman's own health history.
FDA Issues Complete Response Letter for INTUNIV(TM) (guanfacine) Extended Release for the Treatment of ADHD in Children and Adolescents
...States, approximately 7.8 percent of all school-aged children, or
about 4.4 million children aged 4 to 17 years, have been diagnosed with ADHD
at some point
in their lives, according to the Centers for Disease Control
and Prevention (CDC).(14) The disorder is also estimated to affect 4.4
percent of US adul...
Wyeth Reports Publication of Phase 3 Data for Bazedoxifene/Conjugated Estrogens, an Investigational Compound Being Studied for the Treatment of Menopausal Symptoms
...ebo- and active-controlled Phase 3 study that evaluated 3,397 healthy, postmenopausal women with an intact uterus aged 40 to 75 years. The primary end point
of the SMART-1 trial was incidence of endometrial hyperplasia at one year. Secondary end points included bone mineral density (BMD) at two years, meno...
R788 in TASKi3 Clinical Trial Does Not Meet Efficacy Endpoints in RA Patients Who Had Previously Failed Biologic Therapies - Results Incongruent
...A biologic failure patients and rose unaccountably between week 6 (at which point
the reported response rates between R788 and placebo were significantly dif...inase inhibitor designed to interrupt the cellular signaling at the trigger point
of inflammation, thereby stopping the progression of the disease. In July 2...
Idenix Pharmaceuticals Successfully Completes Proof-of-Concept Study of IDX184 for the Treatment of Hepatitis C Virus (HCV)
...lopments may cause these views, expectations and beliefs to change. However, while Idenix may elect to update these forward-looking statements at some point
in the future, it specifically disclaims any obligation to do so.
Teeth and Gums Also Benefit from the Healing Power of Aloe Vera
...genic oral microflora -- disease-causing bacteria -- in the mouth. The ability of aloe vera tooth gel to successfully perform that function has been a point
of contention for some dental professionals. However, the study compared the germ-fighting ability of an aloe vera tooth gel to two commercially popul...
New Results From ARTEN Study of Nevirapine Plus Tenofovir and Emtricitabine (TDF/FTC) Versus Boosted Protease Inhibitor Regimen of Atazanavir/Ritonavir Plus TDF/FTC Revealed
...CP and not increase their VIRAMUNE dose to twice a day. The total duration of the once-daily lead-in dosing period should not exceed 28 days, at which point
an alternative regimen may need to be started.
Other side effects that patients have experienced include nausea, fatigue, fever, headache, v...
Reliv International's GlucAffect(TM) Proven Effective in Clinical Study
...fect group achieved statistically significant lower blood sugar levels as well as significant weight loss compared to both their own baseline starting point
and to the results of the people in the placebo group," said Dr. Carl Hastings, Reliv's vice chairman and chief scientific officer, who is a Ph.D. in ...
GNC Unveils Study Results for First and Only Nitric Oxide Product Clinically Proven to Improve Physical Performance at NSCA Conference in Las Vegas
...se power output at the onset of neuromuscular fatigue by an average of 20% and improve physical performance by helping athletes push past their normal point
of exhaustion. This product is designed to increase nitric oxide levels in the body causing a hemodilation effect which expands blood vessels, allowi...
Shoulder Surgery Doesn't Prevent Return to Sports
... with an age range from 47-93. Patients were followed for a minimum of one year.
Researchers noted that activity modification until the six month point
in the rehabilitation protected the shoulder against any consequence of sport, such as a deceleration injury when a golf club hits the ground or a fal...
Rigel's R788 Significantly Improves Rheumatoid Arthritis in Phase 2b Clinical Trial
...ssues, cartilage and bone. Rigel's R788 is a novel, orally available syk kinase inhibitor designed to interrupt the cellular signaling at the trigger point
of inflammation, thereby stopping the progression of the disease.
Conference Call and Webcast Information
Rigel will host a conference ca...
Leading Experts Endorse Bioheart's Muscle Stem Cell MyoCell Therapy
...ch is one stage of the broader MARVEL program, will meet a key efficacy end point
- the six-minute walk." Dr. Carl Pepine, MD, Professor of Medicine, Unive...ials in Europe to date and added that "the myoblast therapy is at this time point
the only stem cell therapy that is making the claim to actually induce neom...
Accumetrics, Inc. Announces GRAVITAS Trial 50 Percent Enrolled
... than 70 sites in the U.S. and Canada, with a total enrollment goal of approximately 2,800 patients.
"We are thrilled to have reached the halfway point
for enrollment in our GRAVITAS trial," said Jeff Dahlen, Ph.D, Vice President, Clinical and Regulatory Affairs of Accumetrics, Inc. "Once complete, GR...
Sanofi-aventis Stands Behind the Safety of Lantus(R)
...possible causal relationship between Lantus(R) (insulin glargine [rDNA] injection) use and the occurrence of malignancies, as the authors of the study point
Clinical studies, which represent the gold standard of evidence, do not indicate an association between insulin glargine and cancer.
New Therapy Found to Prevent Heart Failure
... Boston Scientific, the study's sponsor. The MADIT-CRT Executive Committee stopped the trial on June 22, 2009, when the trial achieved its primary end point
- significant reduction in heart failure or death with CRT-D versus ICD-only. Cardiologist Arthur Moss, M.D., professor of Medicine at the Universi...
Inspiration for 'My Sister's Keeper' Speaks Out
...ensive, in-depth coverage in nearly every major media outlet in the world. The coverage caught the eye of author Picoult, who used it as a jumping off point
for her novel, My Sister's Keeper.
"We stress to people that the book is fiction and that our family is reality," explains Jack Nash. "The realit...
Urologist and Allergist Explore Link Between Allergies and Interstitial Cystitis
... Findings point
to new treatment options and research directions
WASHINGTON, June 19 /PRNewswire-USNewswire/ -- Allergy testing and treatment may offer a new th...
ProFibrix Initiates Phase II Clinical Trial of its Lead Topical Hemostat Product Fibrocaps(TM)
...stone for the company. With focus and dedication we have made
enormous progress over the past two years, and we are on track to bring
Fibrocaps to the point
of market approval."
ProFibrix was founded in 2004 and is headquartered in Leiden, The
Netherlands, with a subsidiary in...
Great Basin Scientific, Inc. Raises $3.6 Million in Bridge Funding to Prepare for Launch of First Product
...e president of development.
Beginning as early as mid-July, several major hospitals will serve as beta-testing sites for Great Basin Scientific's point
of care molecular platform. During beta-testing, clinicians will test the analyzers and provide feedback on process flow and functionality. The testin...
New Poll Finds Disease Prevention is Top Priority for Americans in Health Reform
...rcent agree with the statement that "prevention will save us money"), they strongly support prevention regardless of its impact on costs. Rather, they point
clearly to keeping people healthy as the best reason to invest in prevention, with 72 percent agreeing with the statement that "investing in preventio...
Enrollment in Delcath's Pivotal Phase III Metastatic Melanoma Clinical Trial Achieves Seventy-Five Percent Accrual
...r, announced today that it has achieved the seventy-five percent enrollment point
of its pivotal Phase III clinical trial treating metastatic cutaneous and o...e Officer of Delcath, stated, "Reaching the seventy-five percent enrollment point
represents a significant milestone for our Company as we continue to accele...
SCAI Statement on the BARI 2D Trial (Bypass Angioplasty Revascularization Investigation With Diabetes Trial) Presented at the American Diabetes Association (ADA) Annual Scientific Sessions and Published in The New England Journal of Medicine
...T plus revascularization - all patients received an angiogram to determine the type and severity of blockage(s) in the arteries. This is an important point
to understand: it is these sicker patients, who did not meet the inclusion criteria for the trial based on the diagnostic angiogram, who receive the g...
Advance in Bowel Cancer Test Research
...ople aged 50 years and over is a powerful tool for reducing the impact of the disease in Australia.
"If we can develop a screening test that can point
to the presence of clinically important pre-cancerous adenomas which are then removed during follow-up colonoscopy, we will actually be able to preven...
PharmAthene Submits Proposal to BARDA in Response to Broad Agency Announcement for Advanced Research and Development for Valortim(R)
...ant additional non-clinical animal studies, human clinical trials, and manufacturing development work remain to be completed for Valortim(R). At this point
there can be no assurance that Valortim(R) will be shown to be safe and effective and approved by regulatory authorities for use in humans.
PROTECT-1 Phase II/III Induction-Stage Results for ChemoCentryx's Traficet-EN(TM) Presented in Oral Session at DDW 2009 Conference
...e in the Crohn's Disease Activity Index (CDAI) score of at least 70 points over the course of 12 weeks; the more stringent criterion of at least a 100 point
decrease in the CDAI score was also met by week 12. In addition, Traficet-EN treatment resulted in colonoscopic evidence of improvement. These data,...
Back to Normal: Surgery Improves Outcomes for Spine Patients
..., and higher satisfaction than those who chose to go the non-surgical route."
Approximately 80 percent of Americans suffer from back pain at some point
in their lives. Back pain is the most common cause of work-related disability, as well as the most expensive in terms of workers compensation and medi...
TNFerade(TM) Phase III Data Presented at ASCO
...roximately 19.4 months. Although the data still need time and events to reach maturity, we are encouraged by the survival trend being observed at this point
in the trial."
This poster can be accessed online by visiting www.genvec.com and clicking on "Investor Relations" then "Webcasts & Data"...
New Phase 3 Study of Tapentadol Immediate Release Tablets Published in Current Medical Research and Opinion Journal
...pression, or coma. In such patients, even usual therapeutic doses of NUCYNTA(TM) may increase airway resistance and decrease respiratory drive to the point
of apnea. Alternative non-mu-opioid agonist analgesics should be considered and NUCYNTA(TM) should be employed only under careful medical supervision ...
PharmAthene Submits SparVax(TM) Regulatory Strategy to FDA
...cant additional non-clinical animal studies, human clinical trials, and manufacturing development work remain to be completed for SparVax(TM). At this point
there can be no assurance that SparVax(TM) will be shown to be safe and effective and approved by regulatory authorities for use in humans.
New Study Evaluating the ADHD Medication VYVANSE(R) (lisdexamfetamine dimesylate) CII Demonstrated No Change in the Pharmacokinetic Profile of VYVANSE When Coadministered with Prilosec OTC(R) 40 mg (20 mg X 2), a Commonly Used Proton Pump Inhibitor (PPI)
...States, approximately 7.8 percent of all school-aged children, or about 4.4 million children aged 4 to 17 years, have been diagnosed with ADHD at some point
in their lives, according to the US Centers for Disease Control and Prevention (CDC). The disorder is also estimated to affect 4.4 percent of US adul...
Terumo Heart, Inc. Reaches Clinical Milestone as the 100th Patient Worldwide Receives the DuraHeart(TM) Left Ventricular Assist System
...eve," said Chisato Nojiri, M.D., Ph.D., Chairperson and Chief Medical Officer, Terumo Heart, Inc. "The implanting of the 100th patient is an exciting point
along the road to bringing this important, next-generation technology to the global market, and the implanting of three devices in such a short period...
Shire Announces Study Results of the Effects of INTUNIV(TM) (Guanfacine) Extended Release on Secondary Measures in Children with ADHD and Oppositional Symptoms
...tes, approximately 7.8 percent of all school-aged children, or about 4.4 million US children aged 4 to 17 years, have been diagnosed with ADHD at some point
in their lives, according to the Centers for Disease Control and Prevention (CDC).
ADHD is a psychiatric behavioral disorder that manifests as a ...